

6th May, 2021

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Further to our intimation dated 30th April, 2021, we wish to inform you that the Board of Directors the Company at its meeting held today has, inter-alia, took note / approved the following:

1. Declared an Interim Dividend of Rs. 1.50/- (75 %) per equity share of Rs.2 each for the financial year ended 31st March 2021.
2. Fixed 19th May 2021 as Record Date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
3. Approved the Audited standalone and consolidated financial results (**Annexure-1**) of the Company as per Indian Accounting Standards for the year ending 31st March, 2021 along with Auditors Report (**Annexure – 2**). We also enclose a Press Release issued by the Company (**Annexure 3**) and an investor presentation in this regard (**Annexure 4**).
4. Retirement of Mr. R Ravichandran (DIN: 01920603), Independent Director of the Company effective 11th May 2021 (Close of Business hours) upon completion of his tenure.
5. Appointment of Mr Dinesh R G (ACS 42539) as the Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with effect from 6th May 2021. (**Annexure-5**)
6. Incorporation of a wholly owned subsidiary in India namely M/s. Caplin Onco Limited for carrying out Oncology specific business.

We hereby confirm and declare that the Statutory Auditors of the Company i.e., M/s. CNGSN & Associates LLP, Chartered Accountants, Chennai, have issued the audit report on Standalone and Consolidated Financial Statements of the Company for the year ended 31st March, 2021 with unmodified opinion.

The meeting commenced at 10.30 A.M and concluded at 12.35 P.M.

Kindly take the same on your records.

Sincerely Yours
For Caplin Point Laboratories Limited


Avaneesh Singh
Compliance Officer (Interim)
Encl: A/a



CAPLIN POINT LABORATORIES LIMITED		
STANDALONE BALANCE SHEET As at March 31, 2021		
<i>(All amounts are in ₹ crores except share data unless otherwise stated)</i>		
Particulars	As at March 31, 2021	As at March 31, 2020
ASSETS		
(1) Non-Current Assets		
(a) Property, plant and equipment	177.93	161.72
(b) Capital work-in-progress	1.36	3.77
(c) Intangible assets	3.60	3.39
(d) Right of use Assets	1.15	1.81
(e) Investments in Subsidiaries, Associates and Joint venture	137.98	135.21
(f) Financial assets		
(i) Investments	0.66	0.33
(ii) Loans & Advances	3.49	2.21
(g) Income tax assets (Net)	2.17	2.15
Sub-total-Non current assets	328.34	310.59
(2) Current Assets		
(a) Inventories	24.87	22.37
(b) Financial assets		
(i) Investments	10.54	60.23
(ii) Trade receivables	98.46	218.98
(iii) Cash and cash equivalents	148.82	36.84
(iv) Bank balances other than (iii) above	216.67	21.43
(v) Loans & Advances	25.10	20.45
(c) Other current assets	8.20	0.44
Sub-total-Current assets	532.66	380.74
Total	861.00	691.33
EQUITY AND LAIBILITIES		
(1) Equity		
Equity share capital	15.13	15.13
Other equity	743.55	584.78
Sub-total-Total Equity	758.68	599.91
(2) Liabilities		
(A) Non-Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	-	0.02
(ii) Lease Liabilities	0.53	1.28
(b) Deferred tax liabilities (Net)	20.97	22.14
(c) Other non current liabilities	3.49	3.72
Sub-total-Non current liabilities	24.99	27.16
(B) Current Liabilities		
(a) Financial liabilities		
(i) Trade payables	70.10	51.41
(ii) Lease Liabilities	0.79	0.85
(iii) Borrowings	0.01	0.27
(iv) Other current liabilities	6.43	10.86
(b) Provisions	-	0.87
Sub-total-Current liabilities	77.33	64.26
Total	861.00	691.33



CAPLIN POINT LABORATORIES LIMITED

Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2021

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Financial Year Ended	Financial Year Ended
	31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
	(1) (Audited)	(2) (Unaudited)	(3) (Audited)	(4) (Audited)	(5) (Audited)
	INR In Crs				
Income:					
I Revenue from operations	122.88	123.16	100.12	482.68	527.83
II Other income (Refer Note 5)	7.36	3.98	33.01	18.62	65.97
III Total Income (I+II)	130.24	127.14	133.13	501.30	593.80
IV Expenses:					
a. Cost of materials consumed	32.97	32.05	20.39	112.48	95.73
b. Purchase of traded goods	20.21	13.28	29.35	82.92	143.18
c. Changes in inventories of finished goods, stock in trade and work in progress	0.59	2.77	(3.36)	(0.57)	(0.74)
d. Employee benefit expenses	7.31	7.34	4.76	26.59	25.00
e. Finance cost	0.03	0.04	0.05	0.17	0.18
f. Depreciation & Amortisation Expenses	5.97	5.61	5.68	22.44	19.65
g. Other Expenses	18.52	10.74	10.46	47.33	57.66
h. Total Expenses	85.60	71.83	67.33	291.36	340.66
V Profit before exceptional items and Tax (III-IV)	44.64	55.31	65.80	209.94	253.14
VI Exceptional items			-	-	-
VII Profit Before Tax (V-VI)	44.64	55.31	65.80	209.94	253.14
VIII Tax Expenses					
(1) Current Tax	13.12	14.07	15.68	54.88	55.89
(2) Deferred Tax (Refer Note 4)	0.03	(0.24)	(0.01)	(1.17)	(0.40)
Total Tax Expenses	13.15	13.83	15.67	53.71	55.49
IX Net Profit for the period (VII-VIII)	31.49	41.48	50.13	156.23	197.65
X Other Comprehensive Income/ (Loss) - Net of Tax					
A. Items that will not be re-classified to profit or loss					
i) Remeasurements of Defined Benefit Plan	(0.16)	-	(0.09)	0.22	(0.33)
XI Total Comprehensive Income For The Period (IX+X)	31.33	41.48	50.04	156.45	197.32
XII Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.13	15.13	15.13	15.13	15.13
XIII Other equity	-	-	-	743.55	584.78
XIV Earnings Per Share (EPS) based on face value Rs 2/- per Equity share					
(a) Basic (in Rupees)	4.16	5.48	6.63	20.65	26.13
(b) Diluted (in Rupees)	4.07	5.45	6.59	20.45	25.95
	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)	Annualised



Notes :

- 1) The above standalone financial results for the quarter and year ended March 31, 2021 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 6th May, 2021
- 2) The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The Company elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended 31st March, 2020 and remeasured its deferred tax liabilities basis the rates prescribed in the said section. The Company recognized an amount of Rs. 630.63 Lacs towards reversal of deferred tax liability during the year ended 31st March, 2020 on account of the remeasurement
- 5) Other Income and Profits Before Tax for the year ended March 31,2021 includes Dividend of Rs. 3.05 Crs as against Rs.32.90 Crs for the year ended March 31, 2020 , received from our wholly owned subsidiary Caplin Point Far East Limited, Hong Kong.
- 6) Revenue from operations is disclosed net of Goods and Service Tax


As the out-break continues to evolve,the company will closely monitor any material changes to future economic conditions.Based on the assessment done by the management of the Company,there is no significant/material impact of COVID-19 on the results for the quarter and year ended March 31,2021
- 8) The Board of Directors at their meeting held on Thursday,6th May 2021 approved interim dividend of Rs.1.50 (7.5%) per equity share of Rs.2 each for the Financial Year 2020-21
- 9) Results for the year ended 31st March, 2021 presented above have been audited by the Statutory Auditors of the company. An unqualified opinion has been issued by them thereon

During the Quarter and year ended March 31, 2021 the Company has allotted NIL equity shares of Rs. 2/- each under the
- 10) Employees Stock Option Plan 2015 and Employees Stock Option Plan 2017 as against allotment of NIL equity shares in the quarter ended March 31, 2020 and allotment of 12500 equity shares in the year ended March,31 2020
- 11) The figures for the quarters ended 31st March, 2021 and 31st March, 2020 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which was subject to limited review
- 12) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date: 6th May,2021



For and on behalf of the Board


Dr. Sridhar Ganesan
Managing Director

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2021		
(All amounts are in ₹ crores except share data unless otherwise stated)		
	For the Year Ended March 31, 2021	For the year ended March 31, 2020
A. Cash Flow from Operating Activities		
Profit before tax	209.94	253.12
<u>Adjustments for:</u>		
Depreciation and Amortisation	22.44	19.65
Finance costs	0.17	0.18
Govt Grant	(0.80)	(0.54)
(Profit)/Loss on sale of fixed assets	0.06	0.04
Employee Stock option Scheme Expense	3.29	1.49
Unrealised Foreign Exchange Fluctuation Loss (Gain)	0.19	(13.76)
Fair value gain on financial instruments through profit or loss	4.39	(0.49)
Realised gain on Financial Assets	(6.38)	(4.85)
Dividend Income	(3.05)	(32.91)
Interest income	(12.56)	(1.40)
	217.69	220.53
Operating Profit before Working Capital changes		
<u>Adjustments for :</u>		
(Increase) / Decrease in inventories	(2.50)	1.15
(Increase) / Decrease in Trade receivables	120.52	(79.48)
(Increase) / Decrease in Loans	(4.73)	3.22
Increase/(Decrease) in Trade payables ,Current Liabilities & Provisions-Long and Short Term	18.57	(8.06)
CASH GENERATED FROM OPERATIONS	349.55	137.36
Income tax Paid	(54.90)	(50.35)
Net Cash inflow / (outflow) from Operating activities	294.64	87.01
B. Cash Flow from Investing Activities		
Sale / (Purchase) of investments	44.97	9.88
Investment in Subsidiaries	(0.37)	(35.29)
Sale / (Purchase) of fixed assets (including CWIP)	(42.55)	(49.18)
Interest received	4.81	1.52
Dividend received	3.05	32.91
Income tax on Dividend income	-	(5.75)
Realised gain on Financial Assets	6.38	4.85
Net Cash inflow / (outflow) from Investing activities	16.29	(41.06)
C. Cash Flow from Financing Activities		
Proceeds from exercise of employee stock options*	-	0.00
Increase/(Decrease) in Long and Short term Borrowings	(0.27)	(0.26)
Interest paid	(0.17)	(0.14)
Dividend paid (including Dividend distribution tax paid)	(3.03)	(32.52)
Net Cash inflow / (outflow) from Financing activities	(3.47)	(32.92)
Net increase / (decrease) in cash and cash equivalents during the year D=(A+B+C)	307.46	13.03
Cash and Cash Equivalents as at the beginning of the year (E)	55.61	42.53
Effect of exchange rate changes on cash and cash equivalents (F)	(0.19)	0.05
Cash and Cash Equivalents as at the end of the year (G=D+E+F)	362.88	55.61
Less: Deposit under Lien (H)	0.36	5.00
Net Cash and Cash Equivalents as at the end of the year (I=G-H)	362.52	50.61
Notes:		
* Includes Rs 25,000 for year ended Mar'20		
The above Standalone Statement of Cash Flows has been prepared under the "Indirect method" as set out in Ind AS 7, 'statement of Cash Flows'.		



Indhan



CAPLIN POINT LABORATORIES LIMITED		
CONSOLIDATED BALANCE SHEET As at March 31, 2021		
(All amounts are in ₹ Crores except share data unless otherwise stated)		
Particulars	As at March 31, 2021	As at March 31, 2020
ASSETS		
(1) Non-Current Assets		
(a) Property, Plant and Equipment	296.96	265.63
(b) Capital work-in-progress	13.82	20.12
(c) Intangible assets	7.29	5.07
(d) Rou Assets	1.15	1.81
(e) Financial Assets		
(i) Investments	0.66	0.56
(ii) Loans & Advances	7.92	5.38
(f) Income tax assets (Net)	-	4.67
Sub-total-Non current assets	327.80	303.24
(2) Current Assets		
(a) Inventories	179.00	238.23
(b) Financial Assets		
(i) Investments	10.54	60.23
(ii) Trade Receivables	279.36	228.96
(iii) Cash and Cash equivalents	231.57	49.93
(iv) Bank balances other than (iii) above	228.00	173.50
(v) Loans & Advances	98.90	68.30
(c) Other Current Assets	8.44	3.38
Sub-total-Current assets	1,035.81	822.53
Total	1,363.61	1,125.77
Equity and Liabilities		
(1) Equity		
Equity Share capital	15.13	15.13
Other Equity	1,170.70	932.79
Equity attributable to shareholders of the company	1,185.83	947.92
Non controlling interest	17.54	8.66
Sub-total-Total Equity	1,203.37	956.58
(2) Liabilities		
(A) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	0.02
(ii) Lease Liabilities	0.53	1.28
(b) Deferred Tax Liabilities (Net)	1.16	10.11
(c) Income tax Liability (Net)	0.33	-
(d) Other non current liabilities	15.37	13.45
Sub-total-Non current liabilities	17.39	24.86
(B) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	17.07	36.46
(ii) Lease Liabilities	0.79	0.85
(iii) Trade Payables	88.50	64.14
(iv) Other Current Liabilities	36.41	41.97
(b) Provisions	0.08	0.91
Sub-total-Current liabilities	142.85	144.33
Total	1,363.61	1,125.77



CAPLIN POINT LABORATORIES LIMITED

Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096
CIN - L24231TN1990PLC019053, Phone Nos. 044-2496 8000, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

AUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED 31st MARCH 2021

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

Particulars	Three Months Ended			Financial Year Ended	Financial Year Ended
	31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
	(1)	(2)	(3)	(4)	(5)
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	INR in Crs				
Income:					
I Revenue from operations	278.71	274.39	215.23	1,061.29	863.20
II Other income	9.46	5.82	19.63	23.54	41.33
III Total Income (I+II)	288.17	280.21	234.86	1,084.83	904.53
IV Expenses:					
a. Cost of materials consumed	39.44	37.21	23.81	129.82	108.12
b. Purchase of traded goods	103.28	50.81	209.39	259.57	500.14
c. Changes in inventories of finished goods, stock in trade and work in progress	(24.04)	35.88	(121.77)	82.35	(195.10)
d. Employee benefit expenses	25.87	25.51	18.53	102.53	67.76
e. Finance cost	0.32	0.28	0.17	1.59	0.32
f. Depreciation & Amortisation Expenses	9.86	9.27	8.40	36.97	31.62
g. Other Expenses	48.47	41.05	31.46	158.38	122.21
h. Total Expenses	203.20	200.01	169.99	771.21	635.07
V Profit before exceptional items and Tax (III-IV)	84.97	80.20	64.87	313.62	269.46
VI Exceptional items	-	-	-	-	-
VII Profit Before Tax (V-VI)	84.97	80.20	64.87	313.62	269.46
VIII Tax Expenses					
(1) Current Tax	16.60	16.67	18.17	71.14	61.84
(2) Deferred Tax (Refer Note 4)	0.45	(2.61)	(2.16)	(8.96)	(7.46)
Total Tax Expenses	17.05	14.06	16.01	62.18	54.38
IX Net Profit for the period (VII - VIII)	67.92	66.14	48.86	251.44	215.08
X Other Comprehensive Income - Net of Tax					
A. Items that will not be re-classified to profit or loss					
i) Remeasurements of Defined Benefit Plan	(0.29)	-	(0.30)	0.32	(0.70)
ii) Surplus on acquisition of subsidiary	-	-	1.99	-	1.99
B. Items that will be re-classified to profit or loss					
i) Exchange difference in translating the financial statements of foreign operations	2.51	(3.36)	9.63	(7.48)	15.39
XI Total Comprehensive Income For The Period (IX + X)	70.14	62.78	60.18	244.28	231.76
XII Profit attributable to:					
Owners of the Company	66.37	64.46	48.89	242.28	215.00
Non- controlling interests	1.54	1.68	(0.03)	9.16	0.08
	67.92	66.14	48.86	251.44	215.08
XIII Total Comprehensive Income For The Period attributable to					
Owners of the Company	68.60	61.11	60.21	235.12	231.68
Non- controlling interests	1.54	1.67	(0.03)	9.16	0.08
	70.14	62.78	60.18	244.28	231.76
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.13	15.13	15.13	15.13	15.13
XV Other equity excluding Non-controlling interest	-	-	-	1,170.70	932.79
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share					
(a) Basic (in Rupees)	8.78	8.52	6.46	32.03	28.42
(b) Diluted (in Rupees)	8.64	8.46	6.41	31.71	28.20
	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Annualised)	Annualised



Notes :

- 1) The above consolidated financial results for the quarter and year ended March 31, 2021 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 6th May, 2021
- 2) The consolidated financial results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The Company elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended 31st March, 2020 and remeasured its deferred tax assets and liabilities basis the rates prescribed in the said section. The Company recognized an amount of Rs. 563.90 Lacs towards reversal of deferred tax liability(net) during the year ended 31st March, 2020 on account of the remeasurement for entities based in India
- 5) During the Quarter and year ended March 31, 2021 the Company has allotted NIL equity shares of Rs. 2/- each under the Employees Stock Option Plan 2015 and Employees Stock Option Plan 2017 as against allotment of NIL equity shares in the Quarter ended March 31, 2020 and allotment of 12500 equity shares in the year ended March,31 2020.
- 6) Revenue from operations is disclosed net of Goods & Service Tax/ Value Added Tax as applicable
- 7) As the out-break continues to evolve,the Group will closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Company,there is no significant/material impact of COVID-19 on the results for the quarter and year ended March 31,2021.
- 8) Results for the year ended 31st March, 2021 presented above have been audited by the Statutory Auditors of the company. An unqualified opinion has been issued by them thereon
- 9) As the Parent Company's wholly owned subsidiary Caplin Point Far East Limited, Hong Kong had acquired subsidiaries in Nicaragua (in Q1),Honduras (in Q2),Ecuador and Guatemala (in Q4) in FY 19-20, the results of the current quarter and year ended 31st March' 2021 are not comparable with the previous periods.
- 10) The figures for the quarters ended 31st March, 2021 and 31st March, 2020 are the balancing numbers between audited figures in respect of the full financial years and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which was subject to limited review
- 11) Prior year / period figures are regrouped / rearranged wherever necessary.



For and on behalf of the Board

Sridhar Ganesan

Dr. Sridhar Ganesan

Managing Director



Place: Chennai

Date: 6th May,2021

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED March 31, 2021

(All amounts are in ₹ Crores except share data unless otherwise stated)

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020
A. Cash Flow from Operating Activities		
Profit before tax	313.62	269.46
<u>Adjustments for:</u>		
Depreciation and Amortisation	36.97	31.62
Finance costs	1.59	0.32
Govt Grant	(1.06)	(0.76)
Loss (Profit) on sale of fixed assets	0.60	0.04
Employee Stock option Scheme Expense	5.35	3.08
Unrealised Foreign Exchange Fluctuation Loss (Gain)	0.24	(14.31)
Fair value gain on financial instruments through profit or loss	4.39	(0.49)
Realised gain on Financial Assets	(6.38)	(4.97)
Interest income	(18.61)	(7.45)
	336.71	276.54
Operating Profit before Working Capital changes		
<u>Adjustments for:</u>		
(Increase) / Decrease in inventories	59.23	(7.03)
(Increase) / Decrease in Trade receivables	(50.40)	(230.67)
(Increase) / Decrease in Loans	(30.29)	13.95
Increase/(Decrease) in Trade payables ,Current Liabilities & Provisions-Long and Short Term	26.99	31.28
Impact of Foreign currency translation	(7.48)	15.39
CASH GENERATED FROM OPERATIONS	334.76	99.46
Income tax Paid (Net)	(66.14)	(54.76)
Net Cash inflow / (outflow) from Operating activities (A)	268.62	44.70
B. Cash Flow from Investing Activities		
Payment for Acquisition of subsidiaries(Net)	-	9.11
Sale / (Purchase) of investments	44.97	9.88
Proceeds from sale of equity shares/Investment in equity shares	0.23	(0.23)
Sale / (Purchase) of fixed assets (Including CWIP)	(73.34)	(76.74)
Interest received	13.55	4.25
Income tax on Dividend income	-	(5.75)
Realised gain on Financial Assets	6.38	4.97
Net Cash inflow / (outflow) from Investing activities (B)	(8.21)	(54.51)
C. Cash Flow from Financing Activities		
Proceeds from exercise of employee stock options*	-	0.00
Proceeds from issue of CCPS (Net of Cost)	-	113.00
Expenses for Increasing the Authorised share capital	-	(0.22)
Increase/(Decrease) in Long and Short term Borrowings	(19.41)	(0.22)
Interest paid	(1.54)	(0.27)
Dividend paid(including Dividend distribution tax paid)	(3.03)	(32.52)
Net Cash inflow / (outflow) from Financing activities (C)	(23.98)	79.77
Net increase / (decrease) in cash and cash equivalents during the year (D=A+B+C)	236.43	69.96
Cash and Cash Equivalents as at the beginning of the year (E)	220.77	150.66
Effect of exchange rate changes on cash and cash equivalents (F)	(0.24)	0.17
Cash and Cash Equivalents as at the end of the year (G=D+E+F)	456.96	220.79
Less: Deposit under Lien (H)	4.61	9.13
Net Cash and Cash Equivalents as at the end of the year (I=G-H)	452.35	211.64

Notes:

* Includes Rs 25,000 for year ended Mar'20

The above Consolidated Statement of Cash Flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'statement of Cash Flows'.





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

S. NEELAKANTAN
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

K. PARTHASARATHY
B.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad., CWA., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

V. VIVEK ANAND
B.Com., FCA

E.K. SRIVATSAN
B.Com., FCA

PRANAY.J.SHAH
B.Com., FCA

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To the Board of Directors of Caplin Point Laboratories Limited

Report on the audit of the Standalone Annual Financials Results

Opinion

We have audited the accompanying standalone Annual financial results ("the Statement") of **Caplin Point Laboratories Limited** ("hereinafter referred to as the "Company") for the year ended 31st March 2021, attached here with, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (listing Regulations') as amended. Attention is drawn to the fact that the figures for the quarter ended March 2021 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March 2021 as well as the year to date results for the period from 1st April 2020 to 31st March 2021.



Ram

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143 (10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's Responsibilities for the Standalone Annual Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



Ram

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 (3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a



Sam

material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Chennai
Date : 06th May 2021



for M/s **CNGSN & Associates LLP**
Chartered Accountants
Firm's Registration No.: 004915S/S200036

B. Ramakrishnan

B Ramakrishnan
Partner

Membership No. : 201023
UDIN : 21201023AAAAAB1414



CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43
Vijayaraghava Road, T.Nagar, Chennai - 600 017 India.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

S. NEELAKANTAN
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

K. PARTHASARATHY
B.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad., CWA., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

V. VIVEK ANAND
B.Com., FCA

E.K. SRIVATSAN
B.Com., FCA

PRANAY.J.SHAH
B.Com., FCA

Independent Auditors' Report

To
The Board of Directors
Caplin Point Laboratories Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Caplin Point Laboratories Ltd (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), its associate for the year ended 31 March 2021, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid consolidated annual financial results:

A. includes the financial statement / results of the following:

Name of the entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud LLP, India	Subsidiary
Caplin Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point Laboratories Colombia SAS	Subsidiary
Hainan Join town Caplin Point Pharmaceutical Company Limited,	Associate
Caplin Point (S) PTE. LTD, Singapore	Wholly owned subsidiary



Subsidiaries of Caplin Far East Limited, Hong Kong	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Wholly owned subsidiary
Nuevos Eticos Neo Ethicals S.A - Guatemala	Subsidiary
Neoethicals CIA.LTDA - Ecuador	Wholly owned subsidiary
Drogueria Saimed de Honduras S.A.	Wholly owned subsidiary
Neo Ethicals S.A - Nicaragua	Wholly owned subsidiary

are presented in accordance with the requirements of Regulation 33 of the Listing Regulations as amended; and

gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income comprising of net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group and its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group including its associate and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in



Raw

CHARTERED ACCOUNTANTS

compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group and of its associate and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group and of its associate and jointly controlled entities are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one



A handwritten signature in black ink, appearing to read "sam".

CHARTERED ACCOUNTANTS

- resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
 - Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associate to express an opinion on the consolidated annual financial results.

We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



A handwritten signature in black ink, appearing to read "J. Anu".

We also performed procedures in accordance with the circular No CIR/CFD/CMD 1/44/2020 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The consolidated annual financial results include the audited financial results of eight subsidiaries whose financial statements reflect total assets (before consolidation adjustments) of Rs. 761.77 Crore as at 31 March 2021, total revenue (before consolidation adjustments) of Rs. 868.38 crores and total net profit after tax (before consolidation adjustments) of Rs. 179.10 crores and the Group's share of net loss after tax (before consolidation adjustments) of Rs. 0.04 crore of one associate for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements of these entities have been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Board of Directors.

The consolidated annual financial results include the results for the quarter ended 31 March 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

for M/s **CNGSN & Associates LLP**
Chartered Accountants

Firm's Registration No.: 004915S/S200036



Place: Chennai
Date: 06th May 2021

B. Ramakrishnan

B Ramakrishnan
Partner

Membership No. : 201023
UDIN: 21201023AAAAAC7526



Press Release

For Immediate Release

Q4 Revenue up 30%, Total Revenue for the year crosses 1000 Cr

Total Revenue at 1085 Cr, PAT at 251 Cr (23%), Cash Reserves at 470 Cr

Chennai, May 6th, 2021: Caplin Point Laboratories Limited (CPL) (BSE: CAPPL (524742), NSE: CAPLIPOINT) today reported its financial results for the Quarter and year ended March 31st, 2021

Consolidated Results Highlights:

- ✓ In line with company's commitment, Top line of 2015 becomes Bottom line of 2021
- ✓ Cash and Cash Equivalent at Rs 470 Cr at 31st March'21 as against Rs 284 Cr at 31st March'20. Parent Company's Cash and Cash equivalent rises from Rs. 119 Cr in Mar'20 to Rs. 376 Cr in Mar'21, despite investment of Rs. 31 Cr into purchase of Land and Buildings for upcoming projects in 2021/22
- ✓ Inventory stood at Rs 179 Cr as against Rs 238 Cr in Mar'20
- ✓ Receivables stable at 95 days

Particulars (Rs. in Crs)	Q4 FY2021	Q4 FY1920	Growth %	Q3 FY2021	FY2021	FY1920	Growth %
Operating Revenue	278.71	215.23	29.5%	274.39	1061.29	863.20	22.9%
Gross Margin	160.03	103.80	54.2%	150.49	589.55	450.04	31.0%
Gross Margin %	57.4%	48.2%		54.8%	55.6%	52.1%	
EBITDA	95.15	73.44	29.6%	89.75	352.18	301.40	16.8%
EBITDA %	33.0%	31.3%		32.0%	32.5%	33.3%	
PBT	84.97	64.87	31.0%	80.2	313.62	269.46	16.4%
PBT%	29.5%	27.6%		28.6%	28.9%	29.8%	
PAT	67.92	48.86	39.0%	66.14	251.44	215.08	16.9%
PAT%	23.57%	20.8%		23.6%	23.2%	23.8%	

Key Performance Highlights:

Financials (Consolidated) for Q4 and FY21:

- ✓ Total Revenue of Rs 1084.83 Cr for FY21, registered a growth of 20 % over FY20 Total Revenue of Rs 904.53 Cr
- ✓ Q4FY21 Operating Revenues at Rs. 278.71 Cr, registered a growth of 29.5% over Rs. 215.23 Cr in Q4FY20
- ✓ **Gross Margin improved to 57.4% in Q4FY21** from 48.2 % in Q4FY20 and 55.6% in FY21 as a whole year as compared to 52.1% in the previous year
- ✓ **Cash flow From Operations (CFO) at Rs 268.62 Cr in FY21** as against Rs 44.70 Cr for the whole year in FY20

- ✓ With appreciation of INR against USD, exchange gain in FY21 is at Rs. 0.72 Cr as against Rs. 27.37 Cr exchange gain in FY20
- ✓ PAT for FY21 increased by Rs. 36.36 Cr over FY20
- ✓ **Free Cash Flow stood at Rs 195.28 Cr** at March 2021
- ✓ Geographical breakup of Sales: Latin America at 87%; Africa at 5% and US at 8%
- ✓ With Continued focus on Cash Flow, Receivables sustained at 95 days despite growth in sales
- ✓ With focus on need to keep Inventory closer to customers, the current level of inventory is likely to continue at similar levels
- ✓ **How Company Grew in Last 5 and 10 Years**

Particulars	10 Years CAGR	5 Years CAGR	2010-11 to 2020-21 (in Rs. Cr)	2015-16 to 2020-21 (in Rs. Cr)
Operating Revenue	29.4%	28.0%	81 Cr to 1061 Cr	309 Cr to 1061 Cr
Total Revenue	29.3%	28.3%	83 Cr to 1085 Cr	313 Cr to 1085 Cr
EBDITA	40.7%	32.2%	11.5 Cr to 352 Cr	87.33 Cr to 352 Cr
P B T	43.9%	32.6%	8.2 Cr to 313 Cr	76.5 Cr to 314 Cr
P A T	44.6%	33.9%	6.3 Cr to 251 Cr	58.48 Cr to 251 Cr
Cash & Cash Equivalents			21.62 Cr to 470 Cr	68.10 Cr to 470 Cr

Business Highlights

Emerging Markets

- ✓ **Company's Latin American business continues to show strong growth in sales, cashflow and profitability.**
- ✓ **Institutional sales expected to contribute marginally higher in coming quarters, as Company has received Tender orders worth \$18 million in 2 of its markets.**
- ✓ Current breakup of sales: Private Market Sales to Distributors – 60%; Sales to Pharmacies/Retail – 20%; Institutional Sales – 20%.
- ✓ **Company continues to build considerable Cash Reserves, aimed at internally funding the next wave of Capex Projects. Following are the status of each, as on date:**
 - **Oncology Plant for Injectables and OSD (will be executed through its new wholly owned subsidiary, under incorporation) – Design and detail engineering completed. Process equipment ordering – Evaluation under progress**
 - **API Plant (includes US injectable API, OSD API and Oncology API). Targeting complete backward integration from Key Starting Material (KSM) to Intermediates and API – Design and Detail Engineering completed. Tendering for Civil and Mechanical work ongoing.**

- ✓ **Company has commenced exports to Mexico in the last Quarter, supplying Injectables as part of emergency procurement from the country.**
- ✓ Oncology product registrations and R&D for formulations and API underway, in existing and new markets at LatAm, to be catered to by Company's upcoming facility in Chennai
- ✓ **Monthly sales through Company's e-commerce platform 'QuetenX', part of 10X Healthcare portal, increases 37% YoY. Currently catering to around 1,000+ unique customers with 440 SKUs being sold currently, in Guatemala, Nicaragua, Honduras and Ecuador. Next targeted roll out in Dominican Republic.**
- ✓ **Company's CRO wing Amaris Clinical's US FDA audit expected in near future, as two ANDAs filed through partner with Bioequivalence / Bioavailability studies done from this site.**

US & Regulated Markets

- ✓ **Company's US sales has increased 31% YoY, despite pandemic situation prohibiting many outpatient services in the US.**
- ✓ **Company has received 4 ANDA approvals since Jan 2021. Total ANDAs approved is 15 (under Caplin's name – 10, through partners – 5).**
- ✓ Of the above, Company has already launched 8 products in US, with 4 products ready for launch in coming weeks and the balance 3 planned before October'21.
- ✓ **Agreements in place for registration of products in Canada, Australia and Brazil. Revenues expected from these markets in next 18 – 24 months.**
- ✓ **Pre-Mix Injectable Bag line ready for installation with Filing Batches planned in Oct/Nov 2021.**
- ✓ **Design/Detail Engineering for Phase 2 of Injectable plant with 2 more Vial Lines, 1 Lyophilizer Line, 1 PFS line and provision for 1 Pre-Mix Bag line, completed. Total Capex Spend of 110 Cr for Phase 2, to be funded by Parent Company.**
- ✓ Once above expansions are completed, company will have total Capacity of:
 - Liquid Vials : 105 million units (includes Emulsions and Suspension injectables)
 - Ophthalmic : 10 million units (includes Emulsions and Suspension ophthalmic)
 - Pre-Filled Syringes : 18 million units
 - Pre-Mixed Bags: 11 million units, with provision to add 24 million units.
 - Lyophilized Vials : 15 million units
- ✓ API backward integration update: Secondary source API for existing ANDAs – 7 completed with another 16 under development, for both Primary and Secondary source.
- ✓ **Company targets US front end presence in 2023, by which time 30+ ANDAs are likely to be approved/under review.**
- ✓ Overall development pipeline remains robust, with **45+ ANDAs under development with addressable market in US at ~ \$3 Billion.**

COVID-19:

As the outbreak continues to evolve, the Group is closely monitoring the material changes to future economic conditions and is taking all steps necessary to ensure business continuity and employee safety, including vaccination of employees, strict maintenance of masking, social distancing and temperature monitoring etc. Based on the assessment done by the management of the Company, there is no significant/material impact of COVID-19 on the results for the quarter and year ended March 31,2021.

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Subsidiary Caplin Steriles Limited.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was recently awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Caplin

Mr. Avaneesh Singh

Tel: +91 44 24968000

investor@caplinpoint.net

Registered Office

3rd Floor, Ashvich Towers,

No. 3, Developed Plots Industrial Estate, Perungudi,
Chennai – 600 096, Tamil Nadu, INDIA.

Tel : +91 44 2496 8000

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net



**Second Largest wealth creator
for the decade ending 2020**

Proving Remedies
BRINGING SMILES to People

**Investor Presentation
March, 2021**



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.

Content

1 12MFY21 Highlights

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin



Headquarter, Chennai

Content

1 12MFY21 Highlights

- 1.1 12MFY21 Highlights
- 1.2 Update on CAPEX
- 1.3 Robust revenue growth coupled with stable margins
- 1.4 P&L for the Quarter and Year Ended

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin



CP-I plant at Suthukeny, Puducherry

1

Financial Highlights

- ▶ In line with company's commitment, Top line of 2015 becomes bottom line of 2021.
- ▶ Consolidated Total Revenue at INR 1085 Cr for 12MFY21, up 20% YoY, as compared to INR 905 Cr in 12MFY20
- ▶ Q4FY21 Operating Revenue at INR 279 Cr, up 30% YoY, as compared to Rs. 215 Cr in Q4FY20
- ▶ Cash and Cash Equivalent at Rs 470 Cr at 31st March'21 as against Rs 284 Cr as at 31st March'20. Parent Company's Cash and Cash equivalent rises from Rs. 119 Cr in Mar'20 to Rs. 376 Cr in Mar'21, despite investment of Rs. 31 Cr into purchase of Land and Buildings for upcoming projects in 2021/22
- ▶ Cash flow From Operations (CFO) at INR 269 Cr in 12MFY21 as against INR 45 Cr in previous year
- ▶ Inventory stood at INR 179 Cr as at 31st March 2021 as against INR 238 Cr as at 31st March 2020
- ▶ Receivables stable at 95 days as at 31st Mar'21

2

LATAM Business Highlights

- ▶ Company's Latin American business continues to show strong growth in sales, cashflow and profitability.
- ▶ Institutional sales expected to contribute marginally higher in coming quarters, as Company has received Tender orders worth \$18 million in 2 of its markets
- ▶ Current breakup of sales: Private Market Sales to Distributors – 60%; Sales to Pharmacies/Retail – 20%; Institutional Sales – 20%
- ▶ Company has commenced exports to Mexico in the last Quarter, supplying Injectables as part of emergency procurement from the country.
- ▶ Monthly sales through Company's e-commerce platform 'QuetenX', part of 10X Healthcare portal, increases 37% YoY. Currently catering to around 1,000+ unique customers with 440 SKUs being sold currently, in Guatemala, Nicaragua, Honduras and Ecuador. Next targeted roll out in Dominican Republic.

3

US Business Highlights

- ▶ Company's US sales has increased 31% YoY, despite pandemic situation prohibiting many outpatient services in the US.
- ▶ Company has received 4 ANDA approvals since Jan 2021. Total ANDAs approved is 15 (under Caplin's name – 10, through partners – 5)
- ▶ As on date, 8 out of 15 approved ANDAs have been launched, with 4 products ready for launch in the coming weeks and the balance 3 planned before Oct'21.
- ▶ Agreements in place for registration of products in Canada, Australia and Brazil. Revenues expected from these markets in next 18 – 24 months.
- ▶ Pre-Mix Injectable Bag line ready for installation with Filing Batches planned in Oct/Nov 2021.
- ▶ Design/Detail Engineering for Phase 2 of Injectable plant with 2 more Vial Lines, 1 Lyophilizer Line, 1 PFS line and provision for 1 Pre-Mix Bag line, completed. Total Capex Spend of 110 Cr for Phase 2, to be funded by Parent Company.
- ▶ API backward integration update: Secondary source API for existing ANDAs – 7 completed, another 16 under development for both Primary & Secondary source
- ▶ Company targets US front end presence in 2023, by which time 30+ ANDAs are likely to be approved/under review
- ▶ Overall development pipeline remains robust, with 45+ ANDAs under development with addressable market in US at ~ \$3 Billion

Caplin is venturing on a Capex journey of INR ~250-300 cr. to widen its product portfolio and backward integrate majority of the products

Capacity expansion and Maintenance Capex

- ▶ Pre-Mix Injectable Bag line ready for installation with Filing Batches planned in Oct/Nov 2021.
- ▶ Pre-Filled syringe line also to be added before mid-2022
- ▶ Plans underway to add 2 more Vial lines, one with high volume Lyophilization capacity and another dedicated line for Injectable Emulsions
- ▶ Annual maintenance for the Pondicherry plant

INR 30-35 cr

Greenfield Facilities / Acquisition

- ▶ Oncology Plant for Injectables and OSD (will be executed through its new wholly owned subsidiary, under incorporation) –
- ▶ Design and detail engineering completed. Process equipment ordering – Evaluation under progress
- ▶ General Category facility for Oral Solid and Semi Solid dosages, for existing LatAm markets
- ▶ Company has already acquired Land with 4 Civil buildings in place, in Chennai, which will be developed into dedicated Oncology products plant


INR 160-165 cr

Backward Integration

- ▶ Company targets being backward integrated with own APIs for 70% of all filings in US by 2024, a critical differentiator for Generic Injectables
- ▶ Company working on a potential acquisition opportunity for an API facility, If unsuccessful, construction to start immediately on own API plant, for which land acquisition of 18.67 acres has been completed
- ▶ API Plant (includes US injectable API, OSD API and Oncology API). Targeting complete backward integration from Key Starting Material (KSM) to Intermediates and API – Design and Detail Engineering completed. Tendering for Civil and Mechanical work ongoing.

INR 70-100 cr

Robust quarterly revenue growth coupled with stable margins



P&L for the Quarter and Year Ended March 2021 – Consolidated

Value (INR Cr)	Q4 FY21	Q4 FY20	YoY (%)	Q3 FY21	QoQ (%)	12M FY21	12M FY20	YoY (%)
Revenue from Operation	278.71	215.23	29.5%	274.39	1.57%	1061.29	863.20	22.9%
Other Income	9.46	19.63		5.82		23.54	41.33	
Total Revenue	288.17	234.86	22.7%	280.21	2.8%	1084.83	904.53	19.9%
Cost of Goods sold	118.68	111.43	6.51%	123.90	-4.2%	471.74	413.16	14.2%
Gross Profit	160.03	103.80	54.2%	150.49	6.3%	589.55	450.04	31.0%
<i>Gross Profit Margin (on Rev from Operations)</i>	57.4%	48.2%		54.8%		55.6%	52.1%	
Employee Benefit Expenses	25.87	18.53	39.6%	25.51	1.4%	102.53	67.76	51.3%
Research and Development expenses	13.34	15.77	-15.4%	15.15	-11.9%	53.69	53.01	1.3%
Other operating expenses	35.13	15.69	123.9%	25.90	35.6%	104.69	69.20	51.3%
Total expenditure	74.34	49.99	48.7%	66.56	11.7%	260.91	189.97	37.3%
EBITDA	95.15	73.44	29.6%	89.75	6.02%	352.18	301.40	16.8%
<i>EBITDA Margin</i>	33.0%	31.3%		32.0%		32.5%	33.3%	
Depreciation and Amortisation	9.86	8.40	17.4%	9.27	6.36%	36.97	31.62	16.9%
EBIT	85.29	65.04	31.1%	80.48	6.0%	315.21	269.78	16.8%
<i>EBIT Margin</i>	29.6%	27.7%		28.7%		29.1%	29.8%	
Finance Cost	0.32	0.17		0.28		1.59	0.32	
Profit Before Tax	84.97	64.87	31.0%	80.20	5.95%	313.62	269.46	16.4%
<i>PBT Margin</i>	29.5%	27.6%		28.6%		28.9%	29.8%	
Tax	17.05	16.01		14.06	21.3%	62.18	54.38	14.3%
Profit after Tax	67.92	48.86	39.0%	66.14	2.7%	251.44	215.08	16.9%
<i>PAT Margin</i>	23.57%	20.8%		23.6%		23.2%	23.8%	

Content

1 12MFY21 Highlights

2 Understanding Caplin

2.1 Transformation across the decades

2.2 Caplin's core business

2.3 Diversified Product Portfolio with a balanced product mix

2.4 Smart mix of manufacturing and outsourcing; Product capacities

2.5 Research & Development Capabilities

2.6 Delivered Robust Profitable Growth & Returns over the decade


3 Growth engines of Caplin

4 More about Caplin




CP-IV plant at Gummidipoondi, Chennai

Transformation across the decades



Our core business – Tapping the untapped markets




Caplin covers wide spectrum of pharmaceutical formulations and Therapeutic Segments across the 23 countries with a net revenue of INR 1085 Cr in FY21


* Region wise net revenue split for FY21

Diversified Product Portfolio with a changing product mix

Diversified Product Portfolio with zero reliance on single product / Therapy



Changing product mix



Our Products

- ✓ Tablets
- ✓ capsules
- ✓ Injections (liquid & lyophilized, pre-filled syringes)
- ✓ Ophthalmic
- ✓ Liquid Orals
- ✓ Softgel Capsules
- ✓ Ointments, Creams & Gels
- ✓ Powder for injections
- ✓ Suppositories & Ovules
- ✓ Dermocosmetics
- ✓ Surgicals & Disposables
- ✓ Pre-Mix Bag Formulations
- ✓ Inhalers & Sprays
- ✓ IV infusion

Smart mix of manufacturing, outsourcing; product capacities

40% of the products produced inhouse

60% of the products are outsourced from quality conscious partners in India and China

Exports

India
60%

China
40%



CP I plant:

Generics and Branded Generics

- Liquid injections in Vials, Ampoules and Pre-Filled Syringes.
- Tablets
- Capsules
- Liquid Orals (Syrup & Suspension)
- Soft Gelatin Capsules
- Suppositories and Ovules

INVIMA and WHO-GMP

Suthukeny, Puducherry

CP IV Plant (Part of Caplin Steriles Limited)

Injectables and Ophthalmic

- Vials
- Lyophilized Vials
- Ophthalmic
- Pre-Mixed Bags

US FDA, EU-GMP, and INVIMA

Gummidipoondi, Chennai

Total Annual Product Capacity

1,500 Mn
Tablets

400 Mn
Capsules

12 Mn
Pre-Mix Bags

20 Mn
Liquid Injection in
Ampoules

65 Mn
Liquid Injections in
Vials

6 Mn
Bottles of Liquids

1 Mn
Bottles of Dry Syrups

12 Mn
Pre-Filled
Syringes

12 Mn
Ophthalmic units

220 Mn
Soft Gels

30 Mn
Suppositories

1.2 Mn
Lyophilized Vials

Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Research & Development Capabilities

5 Dedicated Facilities

Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval)

INR 1.6 bn Capex

Continuous capex investment of over INR 1.6 bn over last 5 years towards enhanced manufacturing and R&D capabilities


Expensing R&D

Caplin expenses all R&D expenditure. Total R&D Spends (Capex + Opex) is 25% of FY21 PAT

API


Completed R&D for 22 APIs to be used for backward integration in US and Emerging markets. On track for the DMF filing

R&D expense – Capex + Opex (INR cr)




*FY16 data for 9 months due to change in fiscal year of the company

R&D Team at Caplin (Nos) (*to be updated)









ANDA Pipeline



Caplin ranks #1 in India across all industries, for R&D spend as a percentage of Revenue on average in the past 5 years.*

*Source – CNBC-TV18, Dec 31st 2020

Delivered Robust Profitable Growth & Returns over the years



Target achieved **2015 Top Line is now 2021 Bottom Line**

New Target **To achieve a Cash Surplus of Rs.1000 ~ 1500 Cr in the next 5 years**

*FY16 was only 9 months due to change in fiscal year of the company and therefore the FY16 numbers are Annualized

Content

1 12MFY21 Highlights

2 Understanding Caplin

3 Growth engines of Caplin

4 Appendix



Amaris Clinical - CRO Clinic, Chennai



01

Core business to grow at historical pace...

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at above industry-average pace with margins expected to improve with increased branded generics business

02

... with US Business to boost the growth...

Aspirations to have exceptional compliance record and focus on niche products which continues to be in shortage in US market, Caplin believes US business to be one of its primary engines that will drive growth

03

... backed by enhanced value chain...

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

04

... Strong balance sheet and...

Caplin's DNA of remaining net debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long term vision

05

... Expansion into other geographies and widening of the portfolio

Caplin plans to enter more regulated markets such as Canada, Mexico and Australia in the near to medium term horizon as well as expand its products portfolio

01 | Core business to grow at historical pace...

Overview

LATAM


- **No. 1 Indian player in Central America**
- Increased its LATAM footprint from **two countries to 12 countries within a decade**
- Entry into Pharmacy sales through **Healthcare portal**, for higher margins and offtake

Africa

- **One of the first few Indian pharmaceutical companies to extend to West Africa** with Brand Marketing
- **High Recognition** of CPL's brands across Francophone and Portuguese Africa

Performance

Operating Revenue from LATAM + Africa (INR Cr)



*FY16 was only 9 months due to change in fiscal year of the company and therefore the FY16 numbers are Annualized

Expansion

- ✓ Increasing focus to larger Latin American countries such as Chile, Colombia and expansion in Mexico and Brazil
- ✓ Working on additional 150 formulations specifically targeting 3 expansion areas – Hospital Injectables, Neuropsychiatric products in Brand Marketing and Anti-Cancer products.

Pharmacy automation

- ✓ To increase profitability and augment strong capabilities in the Supply Chain.
- ✓ 'QuetenX', part of 10X Healthcare portal, continues to show strong traction, reaching 900+ unique B2B customers in Latin America

Strategy

End to end business model

- ✓ Acquisition of distributors in LATAM region creates an end to end business model with total control over export, import and distribution

Bottom of the Pyramid

- ✓ Continued focus on the Bottom of the Pyramid, creating a stickiness factor for Caplin's products

Quétenx B2B E-Commerce Sales 2021



Quétenx is the first B2B Marketplace in Central America for Online Pharmacy Purchases



Highlights JAN-APR 2021

- USD 985k** Driven Sales through digital channel 2021
- 1k+** Unique Customers
- 4.2k** Orders through digital channel

USD 246k Monthly Average 2021
 USD 154k Monthly Average 2020
 ▲ **+37%**

Overview

- Invested ~Rs.450 Crore in Capex and Opex for the 5 years since 2014 through internal accruals to enter the US and Regulated markets
- Entered US Market in 2017-18 with launch of Ketorolac Inj, currently owned by Baxter
- Launched 8 products in total in the US, through partners such as Fresenius Kabi, Baxter, Sagent, Xellia, Meitheal and others.
- Signed new agreements for registration of products in Canada, Australia and Brazil. Revenues expected from these markets in next 18 – 24 months

Injectable plant Inspection history

Plant has undergone 3 US FDA and 2 EU GMP audits successfully since 2016

Date	Authority	Observations/ 483 / Warning letter
June 2019	USFDA	2 observations of procedural nature
October 2018	USFDA	No observations
October 2016	USFDA	2 observations of procedural nature
May 2015	EU GMP	No Critical observations
Sep 2018	EU GMP	No Critical observations

Creating the brand Caplin in US market

- ✓ Strengthening the US Credentials by entering niche high value Injectable and Ophthalmic segment
- ✓ Filing a mix of Simple and Complex injectables in US in Caplin's name
- ✓ Planning to have front end presence by 2023 in the US market to launch own label & expand.

Focused on a niche segment

- ✓ The Company believes in focusing on this niche segment as there's a chronic gap between demand and supply in Injectables in the US market, resulting in frequent shortages. Also this segment has seen lesser price erosion comparatively due to these shortages.

Strategy


Strategic Partner

- ✓ Fidelity invested INR 218 Cr. in Caplin Steriles (Caplin's US business) for minority stake.
- ✓ Fidelity is known to be a long term knowledge partner with over 50% of worldwide private investments into Healthcare. This helps bringing us access to a powerful investment platform spanning Asia, Europe and the US.

Capacity expansion & backward integration

- ✓ 3x Capacity expansion ongoing at Caplin Steriles Plant – CP-4
- ✓ API backward integration plan for US business is on track and expected to be completed by Q4FY22
- ✓ Expansion into Pre-Mix Bags, Lyophilized Vials and Pre-Filled Syringes soon.

Transaction Structure




Transaction Details

Objective

- Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio and enhance capacities at Plant.
- **Eight Roads and F-Prime Capital – Fidelity** together bring access to a powerful investment platform spanning **Asia, Europe and the US**.

Key Transaction Highlights

- Caplin Steriles Ltd, subsidiary of Caplin Point Laboratories Ltd. will cater to the rapidly growing demand for **injectable products** in the regulated markets, especially the **US and other Regulated Markets**.
- **Eight Roads Ventures and F-Prime Capital** invests **INR 218Cr for Minority** stake, with cash infusion coming into Caplin Steriles Ltd.
- **Fidelity** known to be a long term knowledge partner with over 50% of worldwide private investments into Healthcare.
- The subsidiary has already filed **20 ANDAs** on its own and through partners with the **US FDA**, with **15 approvals till date**.




Our strategic decisions which will help us in scaling up value chain



These strategic decisions which will help caplin to have a better cost advantage is future, gather better intel on the market it operates in, better understand the market trends and changing customer needs as well as better access to some of its markets

Amaris Clinical – Highlights



Regulatory clearance targeted



State of the Art Technology

Andrew Alliance - Auto Pipetting System




The pipetting robot. This liquid handling robot ensures fully traceable and reproducible experiments by automation of complete laboratory workflows – using conventional pipettes and labware

Hamilton Automated Sample Access Manager (Sam HD)




- ✓ A first of its kind in India, SAM HD is a completely automated sample management system ensuring high integrity and speed of processing
- ✓ Amaris Clinical is the first CRO in India to have this Automated Storage System


Caplin's strong balance sheet acts as an anchor for its vision of perceiving an 'Invisible opportunity'



Stable Receivables over the recent period




Caplin has incurred strong capex in recent years to enable future growth for next 5 years



Company has maintained optimal asset turnover ratio over the years

Caplin had acquired its Channel Partners in Nicaragua, Honduras, Ecuador & Guatemala in FY 20

Caplin is a net debt free company



Caplin is venturing on a Capex journey of INR ~250-300 cr. to widen its product portfolio and backward integrate majority of the products

Content

1 12MFY21 Highlights

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin

4.1 Experienced and Visionary Board of Directors

4.2 Shareholder Information



R&D centre

Experienced and Visionary Board of Directors



Mr. C.C. Paarthipan
Chairman

- ✓ 30+ Years of experience in the pharmaceutical industry
- ✓ Spearheading the group in its multi-pronged growth approach
- ✓ First Gen Entrepreneur with a focus towards bottom of the pyramid



Dr. Sridhar Ganesan
Managing Director

- ✓ 35+ Years experience in Pharmaceutical Industry
- ✓ Previously, held leadership positions in several international assignments
- ✓ The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"
- ✓ Has been a Faculty in BITS



Mr. D.P. Mishra
Director

- ✓ 30+ years experience in the area of Medicines and formulations
- ✓ Post Graduate in Chemistry



Dr. K.C. John
Independent Director

- ✓ 30+ years experience in spheres of technology & entrepreneurship
- ✓ Holds Ph.D from IIM Ahmedabad
- ✓ Visiting Professor at Great Lakes Institute
- ✓ Associated with the global digital communication leader Qualcomm [Fortune 500]

Experienced and Visionary Board of Directors (cont'd)



Dr R Ravichandran
Independent Director

- ✓ Management and Finance professional, having rich experience of 38+ years in manufacturing and services



D Sathyanarayanan
Independent Director

- ✓ 30+ years experience in application dev. & implementation
- ✓ MS from Stanford University and bachelors from IIT-Madras



Dr. C K Gariyali, IAS
Independent Director

- ✓ Retired IAS Officer and holds a Doctorate in Women Studies
- ✓ Was Principal Secretary to the Governor of Tamil Nadu from 2005-08
- ✓ Was Secretary to Hon'ble CM of Tamil Nadu
- ✓ Worked with various International Agencies like World Bank etc.



Mr V Thirumalai
Independent Director


- ✓ 50+ years experience in the field of finance, HR, management & industrial relations
- ✓ Post Graduate in Commerce



R Viswanathan
Independent Director

- ✓ Retired ambassador of India to Argentina, Uruguay & Paraguay – 2007 to 2012
- ✓ Latin American expert, widely renowned for his initiatives bringing Latin America closer to India.

Caplin Shareholding as on 31st March 2021



Share Information (as on 31st March 2021)

NSE Ticker	CAPLIPOINT
BSE Ticker	524742
Market Cap (INR Cr)	3,052
% free-float	30.97%
Free-float market cap (INR Cr)	945
Total Debt (INR Cr)	17
Cash & Cash Equivalents (INR Cr)	470
Shares Outstanding	7,56,42,750
3M ADTV (Shares)*	1,41,029
3M ADTV (INR cr)*	6.66
Industry	Pharmaceuticals

*Source: NSE

Our Products





Caplin Point Laboratories Limited

Investor Relations at Caplin

Avaneesh Singh

+91 44 24968119 investors@caplinpoint.net

BSE 524742

NSE CAPLIPOINT

REUTERS CAPL.NS

© 2018 Caplin Point Laboratories Limited, All Rights Reserved.

"Caplin Point" and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015

S.No	Details of events	Information of such event (s)
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Mr. Dinesh R G has been appointed as Company Secretary, Compliance Officer & KMP of the Company.
2.	Date of appointment / cessation (as applicable) & term of appointment;	w.e.f. 6 th May 2021
3.	Brief profile (in case of appointment);	
	Name of the Company Secretary, Compliance Officer & KMP	Dinesh R G
	ICSI Membership No.	ACS 42539
	Educational Qualification	Associate Member of the Institute of Company Secretaries of India, B.Com (Corporate Secretaryship)
	Work Experience	5+ years of experience in in Corporate Laws, Compliance Management, Securities Laws in reputed Listed entity.

